Review



125 i]-labeled neurotrophic factors recombinant human (rh) epo  (Cell Sciences Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Cell Sciences Inc 125 i]-labeled neurotrophic factors recombinant human (rh) epo
    (A) Intranasal delivery in nM of <t>BDNF</t> 25 min after intranasal delivery (N = 7). (B) Intranasal delivery in nM of BDNF 60 min after intranasal delivery (N = 3).
    125 I] Labeled Neurotrophic Factors Recombinant Human (Rh) Epo, supplied by Cell Sciences Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/125 i]-labeled neurotrophic factors recombinant human (rh) epo/product/Cell Sciences Inc
    Average 90 stars, based on 1 article reviews
    125 i]-labeled neurotrophic factors recombinant human (rh) epo - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS"

    Article Title: Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS

    Journal: Journal of drug targeting

    doi: 10.3109/10611860903318134

    (A) Intranasal delivery in nM of BDNF 25 min after intranasal delivery (N = 7). (B) Intranasal delivery in nM of BDNF 60 min after intranasal delivery (N = 3).
    Figure Legend Snippet: (A) Intranasal delivery in nM of BDNF 25 min after intranasal delivery (N = 7). (B) Intranasal delivery in nM of BDNF 60 min after intranasal delivery (N = 3).

    Techniques Used:

    Concentration of drug 25 min after intranasal delivery in nanograms/mL.
    Figure Legend Snippet: Concentration of drug 25 min after intranasal delivery in nanograms/mL.

    Techniques Used: Concentration Assay

    Concentration of drug 60 min after intranasal delivery in nanograms/mL.
    Figure Legend Snippet: Concentration of drug 60 min after intranasal delivery in nanograms/mL.

    Techniques Used: Concentration Assay

    Western blot examination of activation of the pAkt pathway caused by intranasal delivery of either CNTF or BDNF. (A) Representative western blot of control and CNTF-treated occipital cortex 24 and 48 h after a single intranasal application. Control pAkt protein is on the far right. HPRT was used as a loading control. (B) Densitometric examination of relative amounts of pAkt in CNTF-treated occipital cortex 24, 48, 72, and 96 h after a single intranasal application compared to saline-only control cortex (N=6 for each time point). * indicates significantly different from control. (C) Densitometric examination of relative amounts of pAkt in BDNF-treated frontal cortex 24, 48, 72, and 96 h after a single intranasal application compared to saline-only control cortex (N = 6 for each time point). * indicates significantly different from control.
    Figure Legend Snippet: Western blot examination of activation of the pAkt pathway caused by intranasal delivery of either CNTF or BDNF. (A) Representative western blot of control and CNTF-treated occipital cortex 24 and 48 h after a single intranasal application. Control pAkt protein is on the far right. HPRT was used as a loading control. (B) Densitometric examination of relative amounts of pAkt in CNTF-treated occipital cortex 24, 48, 72, and 96 h after a single intranasal application compared to saline-only control cortex (N=6 for each time point). * indicates significantly different from control. (C) Densitometric examination of relative amounts of pAkt in BDNF-treated frontal cortex 24, 48, 72, and 96 h after a single intranasal application compared to saline-only control cortex (N = 6 for each time point). * indicates significantly different from control.

    Techniques Used: Western Blot, Activation Assay, Control, Saline



    Similar Products

    Image Search Results